President Trump stated on Monday that his administration had reached drug pricing agreements with nine additional pharmaceutical manufacturers. The companies involved in the new deals are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
Under the terms of these agreements, the participating companies committed to providing discounts on outpatient medications to state Medicaid programs. The pricing structure aims to align what states pay for medications with the prices these companies charge in international markets. The affected drugs address various chronic and rare conditions, including hemophilia, liver disease, skin conditions, and certain cancer types.
These nine deals expand the Trump administration’s pharmaceutical pricing initiative to a total of 26 companies, which officials claim represents 90 percent of the domestic pharmaceutical market. The president indicated that the remaining 10 percent of the industry is in the process of joining the arrangement. The administration previously completed similar agreements with 17 other major drugmakers, including Pfizer, Eli Lilly, and Novo Nordisk, as part of its “most favored nation” pricing policy framework initiated through an executive order in May 2025.
The pharmaceutical industry has responded to these agreements by making significant operational adjustments. Companies are investing billions of dollars to relocate manufacturing operations to the United States in response to tariff considerations. Additionally, drugmakers are expanding direct-to-consumer sales channels and utilizing the administration’s TrumpRx platform for medication distribution. Industry analysts note that lower domestic prices are affecting manufacturer revenues, with some companies reporting that increased prescription volumes have not yet fully compensated for reduced per-unit pricing.
U.S. prescription drug prices have historically exceeded international pricing significantly, with average domestic costs running nearly three times higher than overseas prices according to recent analysis. The pharmaceutical industry trade association has previously expressed concerns that most-favored nation pricing policies do not represent the most effective approach to reducing drug costs for American consumers.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI